var data={"title":"Warm autoimmune hemolytic anemia: Clinical features and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Warm autoimmune hemolytic anemia: Clinical features and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Stanley L Schrier, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Carlo Brugnara, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">William C Mentzer, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Jennifer S Tirnauer, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 19, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autoimmune hemolytic anemia (AIHA) due to the presence of warm agglutinins is almost always due to the presence of IgG antibodies that react with protein antigens on the red blood cell (RBC) surface at body temperature. For this reason, they are called &quot;warm agglutinins&quot; even though they seldom directly agglutinate the RBCs.</p><p>This topic review will discuss the clinical features and diagnosis of AIHA due to warm agglutinins [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Treatment of this disorder is discussed separately. (See <a href=\"topic.htm?path=warm-autoimmune-hemolytic-anemia-treatment\" class=\"medical medical_review\">&quot;Warm autoimmune hemolytic anemia: Treatment&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>AIHA is a frequent problem in patients with systemic lupus erythematosus, occurring in up to 10 percent of patients. This subject is discussed separately. (See <a href=\"topic.htm?path=hematologic-manifestations-of-systemic-lupus-erythematosus#H8\" class=\"medical medical_review\">&quot;Hematologic manifestations of systemic lupus erythematosus&quot;, section on 'Autoimmune hemolytic anemia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pathogenesis, diagnosis, and treatment of AIHA associated with the presence of cold agglutinins is discussed separately. (See <a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-cold-agglutinin-disease\" class=\"medical medical_review\">&quot;Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease&quot;</a> and <a href=\"topic.htm?path=cold-agglutinin-disease\" class=\"medical medical_review\">&quot;Cold agglutinin disease&quot;</a> and <a href=\"topic.htm?path=paroxysmal-cold-hemoglobinuria\" class=\"medical medical_review\">&quot;Paroxysmal cold hemoglobinuria&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of factors may initiate the antibody production in warm agglutinin AIHA. This issue is discussed in detail separately. (See <a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs#H11\" class=\"medical medical_review\">&quot;Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs&quot;, section on 'Genesis of antibody production'</a>.) </p><p>Most cases are idiopathic with no underlying disorder or direct cause that can be found.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Underlying causes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Underlying causes or conditions that may be associated with AIHA include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preceding viral infections (usually in children). </p><p/><p class=\"bulletIndent1\">Typical AIHA due to the presence of warm agglutinins has been described in patients with HIV infection. (See <a href=\"topic.htm?path=hematologic-manifestations-of-hiv-infection-anemia#H14\" class=\"medical medical_review\">&quot;Hematologic manifestations of HIV infection: Anemia&quot;, section on 'Antibody-mediated'</a>.)</p><p/><p class=\"bulletIndent1\">A case of AIHA in the setting of acute hepatitis E infection has also been reported [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=hepatitis-e-virus-infection\" class=\"medical medical_review\">&quot;Hepatitis E virus infection&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autoimmune and connective tissue diseases (eg, systemic lupus erythematosus, autoimmune lymphoproliferative syndrome). (See <a href=\"topic.htm?path=hematologic-manifestations-of-systemic-lupus-erythematosus#H8\" class=\"medical medical_review\">&quot;Hematologic manifestations of systemic lupus erythematosus&quot;, section on 'Autoimmune hemolytic anemia'</a> and <a href=\"topic.htm?path=autoimmune-lymphoproliferative-syndrome-alps-clinical-features-and-diagnosis#H1698854\" class=\"medical medical_review\">&quot;Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis&quot;, section on 'Autoimmunity'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immune deficiency diseases, such as common variable immunodeficiency. (See <a href=\"topic.htm?path=clinical-manifestations-epidemiology-and-diagnosis-of-common-variable-immunodeficiency-in-adults#H1193493\" class=\"medical medical_review\">&quot;Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults&quot;, section on 'Autoimmune disease'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malignancies of the immune system (eg, non-Hodgkin lymphoma, chronic lymphocytic leukemia [CLL], with a higher incidence in those treated with purine analogs). (See <a href=\"topic.htm?path=overview-of-the-complications-of-chronic-lymphocytic-leukemia#H13\" class=\"medical medical_review\">&quot;Overview of the complications of chronic lymphocytic leukemia&quot;, section on 'Autoimmune hemolytic anemia'</a> and <a href=\"topic.htm?path=autoimmune-complications-following-purine-analog-therapy#H3\" class=\"medical medical_review\">&quot;Autoimmune complications following purine analog therapy&quot;, section on 'Autoimmune hemolytic anemia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior allogeneic blood transfusion, hematopoietic cell transplantation, or solid organ transplantation [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/4-6\" class=\"abstract_t\">4-6</a>]. (See <a href=\"topic.htm?path=donor-selection-for-hematopoietic-cell-transplantation#H91588735\" class=\"medical medical_review\">&quot;Donor selection for hematopoietic cell transplantation&quot;, section on 'ABO and Rh status'</a> and <a href=\"topic.htm?path=warm-autoimmune-hemolytic-anemia-treatment#H1245452\" class=\"medical medical_review\">&quot;Warm autoimmune hemolytic anemia: Treatment&quot;, section on 'Post-transplant AIHA'</a>.)</p><p/><p>CLL may be a particular problem. It has been estimated that as many as 11 percent of patients with CLL develop AIHA. The incidence is even higher in patients with CLL who are treated with purine analogs such as <a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">fludarabine</a> [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/7,8\" class=\"abstract_t\">7,8</a>], <a href=\"topic.htm?path=pentostatin-drug-information\" class=\"drug drug_general\">pentostatin</a> (2-deoxycoformycin) [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>], or <a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">cladribine</a> (2-chlorodeoxyadenosine) [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>]. Anemia has been severe in some cases, resulting in death [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/9,11\" class=\"abstract_t\">9,11</a>]. Why purine analogs appear to predispose to AIHA in patients with CLL is not clear. One possibility is immune deregulation, which is a common complication when purine analogs are used in this setting [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/12,13\" class=\"abstract_t\">12,13</a>]. In a retrospective French study, a positive direct antiglobulin test (DAT; Coombs test) was found to be an independent adverse prognostic factor for overall survival in CLL [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/14\" class=\"abstract_t\">14</a>]. (See <a href=\"topic.htm?path=overview-of-the-complications-of-chronic-lymphocytic-leukemia#H13\" class=\"medical medical_review\">&quot;Overview of the complications of chronic lymphocytic leukemia&quot;, section on 'Autoimmune hemolytic anemia'</a> and <a href=\"topic.htm?path=autoimmune-complications-following-purine-analog-therapy#H3\" class=\"medical medical_review\">&quot;Autoimmune complications following purine analog therapy&quot;, section on 'Autoimmune hemolytic anemia'</a>.)</p><p>An association of AIHA with babesiosis (<a href=\"image.htm?imageKey=ID%2F110026\" class=\"graphic graphic_picture graphicRef110026 \">picture 1</a>) has been reported; this complication appears to be restricted to individuals who have undergone splenectomy. In a cohort of 86 consecutive individuals treated for babesiosis at a single institution, six developed warm AIHA [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/15\" class=\"abstract_t\">15</a>]. The typical time course of AIHA was two to four weeks after diagnosis, when they had exhibited a response to antimicrobial therapy and had no evidence of parasitemia on their blood smears. All six had undergone splenectomy, whereas 12 of the remaining 80 (15 percent) without AIHA had undergone splenectomy. Only one of the six had received a blood transfusion in the previous two months. All resolved, although four were treated with glucocorticoids for weeks to months, and one was treated with <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>. (See <a href=\"topic.htm?path=warm-autoimmune-hemolytic-anemia-treatment\" class=\"medical medical_review\">&quot;Warm autoimmune hemolytic anemia: Treatment&quot;</a>.)</p><p>As noted below, a case of Evans syndrome in an individual who had undergone splenectomy has also been reported. (See <a href=\"#H7149664\" class=\"local\">'Evans syndrome'</a> below.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A large number of drugs have been implicated as the cause of immune hemolytic anemia. This subject is discussed in depth separately. (See <a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs#H15\" class=\"medical medical_review\">&quot;Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs&quot;, section on 'Drug-related immune hemolysis'</a> and <a href=\"topic.htm?path=hemolytic-anemia-due-to-drugs-and-toxins\" class=\"medical medical_review\">&quot;Hemolytic anemia due to drugs and toxins&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The signs and symptoms of AIHA are nonspecific and common to all types of anemia. The clinical syndrome seen with AIHA of the warm-antibody type varies greatly with the amount and effectiveness of the causative antibody. When the amount is small or the antibody is inefficient at effecting hemolysis, the patient may be asymptomatic even if slightly anemic. More commonly, the patient is moderately to severely anemic.</p><p>The likelihood of a patient with AIHA developing symptoms due to anemia is determined by the severity of the disease, whether the patient is at rest or during exertion, the rapidity with which the anemia develops, and whether there is concurrent illness (eg, underlying cardiac disease). In healthy resting humans, normal oxygen delivery can be maintained by enhanced extraction alone down to a hemoglobin concentration of 8 to 9 <span class=\"nowrap\">g/dL</span> [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/16\" class=\"abstract_t\">16</a>]; when the added compensation of increases in stroke volume and heart rate (and therefore cardiac output) are included, oxygen delivery can be maintained at a hemoglobin concentration as low as 5 <span class=\"nowrap\">g/dL</span> (equivalent to a hematocrit of 15 percent) [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"topic.htm?path=indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult#H2\" class=\"medical medical_review\">&quot;Indications and hemoglobin thresholds for red blood cell transfusion in the adult&quot;, section on 'Role of blood in oxygen delivery'</a>.)</p><p>Symptoms will occur when the hemoglobin concentration falls below this level at rest, at higher hemoglobin concentrations during exertion, or when the cardiac compensation does not occur due to underlying heart disease. The primary symptoms include exertional dyspnea, dyspnea at rest, varying degrees of fatigue, and signs and symptoms of the hyperdynamic state, such as bounding pulses, palpitations, and &quot;roaring in the ears.&quot; (See <a href=\"topic.htm?path=approach-to-the-adult-with-anemia#H11\" class=\"medical medical_review\">&quot;Approach to the adult with anemia&quot;, section on 'Clinical consequences'</a>.)</p><p>The clinical syndrome of AIHA may become life-threatening with more severe anemia. If the hemoglobin falls below a level able to sustain sufficient oxygenation, the patient may become lethargic, confused, and dyspneic with tachycardia. In such patients, corrective measures must be taken at once (eg, glucocorticoids, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a>, transfusion). It is important to remember that wholly compatible blood for transfusion will not be available, but that transfusion with the most compatible, quickly found unit(s) may be life-saving. If not corrected, death from pulmonary edema, myocardial infarction, or fatal cardiac arrhythmia is inevitable.</p><p>Physical examination may show varying degrees of pallor and jaundice. The spleen is commonly enlarged to a moderate degree. Signs and symptoms of cardiac decompensation may be present in those with severe anemia <span class=\"nowrap\">and/or</span> underlying cardiac disease (eg, resting sinus tachycardia, narrow pulse pressure, diaphoresis, pulmonary congestion, peripheral edema, elevated jugular venous pressure). (See <a href=\"topic.htm?path=evaluation-of-the-patient-with-suspected-heart-failure#H5\" class=\"medical medical_review\">&quot;Evaluation of the patient with suspected heart failure&quot;, section on 'Physical examination'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">LABORATORY FINDINGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Laboratory findings in patients with warm agglutinin AIHA include hemolytic anemia of varying severity, a reticulocytosis in response to the anemia, the presence of spherocytic red cells on the peripheral blood smear, and a positive direct antiglobulin (Coombs) test. These findings are discussed in detail below. An example of the baseline characteristics of 60 patients with warm agglutinin AIHA, seen in a French tertiary-care national referral center for adult autoimmune cytopenias is shown in the table (<a href=\"image.htm?imageKey=HEME%2F97136\" class=\"graphic graphic_table graphicRef97136 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/18\" class=\"abstract_t\">18</a>].</p><p class=\"headingAnchor\" id=\"H8244760\"><span class=\"h2\">Hemolytic anemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The laboratory findings in patients with warm agglutinin AIHA are those of hemolytic anemia, with a hemoglobin usually in the range of 7 to 10 <span class=\"nowrap\">g/dL</span> (equivalent to a hematocrit of 21 to 30 percent). As examples of typical values:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one series of 109 patients, the mean hematocrit at presentation was 24 percent, with 30 percent of patients having values below this level [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum levels of lactate dehydrogenase (normal: 140 to 280 International <span class=\"nowrap\">Units/L)</span> were elevated in 93 percent of patients in one series [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/18\" class=\"abstract_t\">18</a>], with median levels of 511 <span class=\"nowrap\">Units/L</span> in a second series [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/20\" class=\"abstract_t\">20</a>]. Those presenting with severe anemia (ie, hemoglobin levels &lt;8 <span class=\"nowrap\">g/dL)</span> may have levels of LDH of 1000 or more [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum haptoglobin levels were reduced in 93 percent of patients, often to unmeasurable levels [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/18\" class=\"abstract_t\">18</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum levels of indirect bilirubin (normal range: 0.2 to 0.7 <span class=\"nowrap\">mg/dL;</span> 3 to 12 <span class=\"nowrap\">micromol/L)</span> were elevated in 87 percent of patients in one series [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/18\" class=\"abstract_t\">18</a>], with median levels in the range of 35 to 51 <span class=\"nowrap\">micromoles/L</span> (2.0 to 3.0 <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p>The combination of an increased serum LDH and reduced haptoglobin is 90 percent specific for diagnosing hemolysis, while the combination of a normal serum LDH and a serum haptoglobin greater than 25 <span class=\"nowrap\">mg/dL</span> is 92 percent sensitive for ruling out hemolysis [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/22,23\" class=\"abstract_t\">22,23</a>]. (See <a href=\"topic.htm?path=diagnosis-of-hemolytic-anemia-in-the-adult#H16\" class=\"medical medical_review\">&quot;Diagnosis of hemolytic anemia in the adult&quot;, section on 'Diagnostic approach'</a>.)</p><p class=\"headingAnchor\" id=\"H8244772\"><span class=\"h2\">Spherocytosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The peripheral blood smear usually shows the presence of spherocytosis (<a href=\"image.htm?imageKey=HEME%2F53523\" class=\"graphic graphic_picture graphicRef53523 \">picture 2</a> and <a href=\"image.htm?imageKey=HEME%2F50601\" class=\"graphic graphic_picture graphicRef50601 \">picture 3</a>), most often single but rarely in doublets [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/24\" class=\"abstract_t\">24</a>], although spherocytes might not be obvious in milder cases [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/18\" class=\"abstract_t\">18</a>]. Red blood cell (RBC) indices may show an elevated mean corpuscular hemoglobin concentration (MCHC), consistent with the presence of spherocytes <span class=\"nowrap\">and/or</span> an increase in the mean corpuscular volume (MCV) indicative of an increase in the percent of reticulocytes. A flow cytometry-based assay for eosin-5&rsquo;-maleimide (EMA) binding to RBCs effectively discriminates between AIHA and hereditary spherocytosis (HS; associated with reduced binding) [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/25\" class=\"abstract_t\">25</a>]. (See <a href=\"topic.htm?path=approach-to-the-adult-with-anemia#H37\" class=\"medical medical_review\">&quot;Approach to the adult with anemia&quot;, section on 'Mean corpuscular hemoglobin concentration'</a> and <a href=\"topic.htm?path=macrocytosis-macrocytic-anemia#H2062517871\" class=\"medical medical_review\">&quot;Macrocytosis/Macrocytic anemia&quot;, section on 'Reticulocytosis'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Positive antiglobulin (Coombs) test</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of warm agglutinin AIHA is based upon detection of antibody <span class=\"nowrap\">and/or</span> complement components on the surface of the RBC (ie, a positive direct antiglobulin [Coombs] test), or, less commonly, in the circulation (ie, a positive indirect antiglobulin [Coombs] test). These are illustrated in the figure and described below (<a href=\"image.htm?imageKey=HEME%2F100639\" class=\"graphic graphic_figure graphicRef100639 \">figure 1</a>). </p><p class=\"headingAnchor\" id=\"H10336022\"><span class=\"h3\">Direct Coombs test</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the direct Coombs test, patient RBCs are washed free of adherent proteins and reacted with antiserum or monoclonal antibodies prepared against the various immunoglobulins, particularly IgG and a fragment of the third component of complement, C3d. When these tests are accurately and specifically performed, 97 to 99 percent of patients with warm agglutinin AIHA will exhibit a positive result with anti-IgG, anti-C3, or both, compared with less than 1 percent of the normal population (<a href=\"image.htm?imageKey=HEME%2F69817\" class=\"graphic graphic_table graphicRef69817 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/26-28\" class=\"abstract_t\">26-28</a>]. The strength of the DAT positivity is generally correlated with the severity of hemolysis, although studies have shown that 7 to 8 percent of hospitalized patients with a positive DAT show no hemolysis, and significant hemolysis may be seen in patients with negative DAT [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/29\" class=\"abstract_t\">29</a>].</p><p>The Coombs test can be quantitated by an estimate of the degree of agglutination, or by more quantitative methods such as ELISA, immunoassay techniques, or flow cytometry [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/30-33\" class=\"abstract_t\">30-33</a>]. The specificity of the antibody can be identified by eluting it from the red cells and testing it against a panel of red cells of known antigenic composition. In most cases, the antigen with which the antibody reacts is not polymorphic and occurs on the cells of almost all donors.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In some instances, the antibody may have specificity for a known blood group antigen. This may be tested using serum in an indirect antiglobulin test or, preferably, using an eluate of the patient's red cells. Often, test cells of rare phenotype (eg, Rh<sub>null</sub>) are necessary to establish a specificity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibodies of IgA or IgM isotype are rare causes of warm AIHA and can be detected with specific anti-IgA or anti-IgM antisera, respectively [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/34-39\" class=\"abstract_t\">34-39</a>]. </p><p/><p class=\"headingAnchor\" id=\"H10336035\"><span class=\"h3\">Indirect Coombs test</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the indirect Coombs test, patient serum is incubated with normal red cells in order to test for the presence of circulating antibodies. This test is generally of little value for making the diagnosis in patients with warm AIHA. Exceptions include the following circumstances:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When testing blood for compatibility for transfusion. (See <a href=\"topic.htm?path=the-incompatible-crossmatch#H15\" class=\"medical medical_review\">&quot;The incompatible crossmatch&quot;, section on 'Autoantibodies'</a> and <a href=\"topic.htm?path=warm-autoimmune-hemolytic-anemia-treatment#H15\" class=\"medical medical_review\">&quot;Warm autoimmune hemolytic anemia: Treatment&quot;, section on 'Red blood cell transfusion'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibodies of low affinity may sometimes be detected by enzymatically digesting the normal red cells used in an indirect antiglobulin test; this procedure increases the affinity between antigen and antibody. Sometimes the specificity of the antibody may be identified by the indirect Coombs alone.</p><p/><p class=\"headingAnchor\" id=\"H10556119\"><span class=\"h3\">Coombs-negative AIHA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In less than 3 percent of patients with warm agglutinin AIHA, the direct Coombs test is negative. If Coombs-negative AIHA is suspected, tests more sensitive and quantitative than this agglutination test may be needed in order to demonstrate the presence of increased numbers of bound immunoglobulin <span class=\"nowrap\">and/or</span> complement molecules on the red cell surface [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/30,31\" class=\"abstract_t\">30,31</a>]. Such tests (ie, the &quot;super&quot; Coombs) may not be generally available, but may be offered by specialized reference laboratories.</p><p>Flow cytometry may play a role in identifying the presence of IgG bound to RBCs in some of the patients presenting with hemolysis and a negative direct Coombs test [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/40\" class=\"abstract_t\">40</a>].</p><p>As an example, in one specialized laboratory employing a radioimmunoassay, the following observations were made concerning the number of IgG molecules per red blood cell in these various scenarios [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/41,42\" class=\"abstract_t\">41,42</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal subjects &ndash; 33 &plusmn; 13</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Average level in patients with Coombs negative AIHA &ndash; 179 &plusmn; 288</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Minimal level required for direct Coombs test positivity &ndash; 335 &plusmn; 72</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Average level in patients with Coombs positive AIHA &ndash; 1397 &plusmn; 1934</p><p/><p class=\"headingAnchor\" id=\"H2760904\"><span class=\"h2\">Reticulocyte response</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The increase in erythropoietin production induced by anemia should raise the reticulocyte percentage above 4 to 5 percent; in one series of patients with AIHA, the median reticulocyte percentage at diagnosis was 9 percent [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>]. The absolute reticulocyte count or the reticulocyte production index are preferred methods to measure the reticulocyte response. (See <a href=\"topic.htm?path=diagnosis-of-hemolytic-anemia-in-the-adult#H3882494893\" class=\"medical medical_review\">&quot;Diagnosis of hemolytic anemia in the adult&quot;, section on 'High reticulocyte count'</a>.)</p><p>Some patients (20 to 37 percent in one series) with acute hemolysis do not have the expected degree of reticulocytosis [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>], and a few may actually have reticulocytopenia [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/43\" class=\"abstract_t\">43</a>]. This is most often due to a lag in marrow responsiveness to hemolytic stress [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>]. Alternatively, the antibody may also be directed against Rh receptors that appear on late orthochromic normoblasts and lead to their recognition and removal by bone marrow macrophages, thus preventing reticulocytes from being formed. Other patients may have direct or indirect bone marrow suppression (eg, parvovirus B19 or other infection). (See <a href=\"topic.htm?path=diagnosis-of-hemolytic-anemia-in-the-adult#H2782676094\" class=\"medical medical_review\">&quot;Diagnosis of hemolytic anemia in the adult&quot;, section on 'Hemolysis without reticulocytosis'</a>.)</p><p class=\"headingAnchor\" id=\"H8244802\"><span class=\"h2\">Other findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thrombocytopenia due to immune destruction of the platelets is occasionally seen, especially in children (Evans-Duane syndrome). </p><p>Signs of intravascular hemolysis (elevated plasma hemoglobin, hemoglobinuria, and hemosiderinuria) are not typical of warm AIHA, but may be present in severe cases.</p><p class=\"headingAnchor\" id=\"H8244746\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of warm agglutinin AIHA is suspected in a patient who presents with the sudden onset of anemia, with laboratory evidence for hemolysis (ie, increased lactate dehydrogenase (LDH), increased indirect bilirubin, reduced to absent haptoglobin). The workup for such patients should include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count with red blood cell indices (eg, MCV, MCH, MCHC), reticulocyte percentage, absolute reticulocyte count, and examination of the peripheral blood smear</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tests for hemolysis, including indirect bilirubin, lactate dehydrogenase, and haptoglobin</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Direct Coombs testing (also called direct antiglobulin test [DAT]), including testing for both IgG and C3 on the red cell surface (<a href=\"image.htm?imageKey=HEME%2F100639\" class=\"graphic graphic_figure graphicRef100639 \">figure 1</a>) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Testing for specificity of the antibody for antigens identified on red blood cells</p><p/><p>The diagnosis of warm agglutinin AIHA is made when all of the following are present (see <a href=\"#H8\" class=\"local\">'Laboratory findings'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemolytic anemia (anemia, high LDH, low haptoglobin, high indirect bilirubin)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of spherocytic red blood cells on the peripheral blood smear</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Positive direct antiglobulin (Coombs) test for the presence of IgG or C3d (after ruling out cold agglutinin disease) or both</p><p/><p>While in most cases there will also be an absolute increase in reticulocytes, such reticulocytosis is a non-specific erythropoietic response to anemia of any cause, and may not be seen initially in some patients. (See <a href=\"#H2760904\" class=\"local\">'Reticulocyte response'</a> above.)</p><p class=\"headingAnchor\" id=\"H7149664\"><span class=\"h1\">EVANS SYNDROME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Evans syndrome (ES), the occurrence of two or more hematologic immune cytopenias, most often AIHA and immune thrombocytopenia, is recognized as a special variant of AIHA [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/44\" class=\"abstract_t\">44</a>]. Although usually described in children, adults may also have ES. In approximately half of the patients, no other immune disorder is recognized, but in half it may be a manifestation of systemic lupus erythematosus, common variable immune deficiency [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/45\" class=\"abstract_t\">45</a>], autoimmune lymphoproliferative disorder [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/46,47\" class=\"abstract_t\">46,47</a>], or another immune disorder [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/48\" class=\"abstract_t\">48</a>]. (See <a href=\"topic.htm?path=autoimmune-lymphoproliferative-syndrome-alps-clinical-features-and-diagnosis#H1698854\" class=\"medical medical_review\">&quot;Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis&quot;, section on 'Autoimmunity'</a>.) </p><p>A report has described new or recurrent ES in two patients who had undergone splenectomy and subsequently developed babesiosis [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/49\" class=\"abstract_t\">49</a>]. The blood smears showed evidence of splenectomy (eg, Howell-Jolly bodies, spherocytes) and very low-level parasitemia, perhaps reflecting dead parasites (<a href=\"image.htm?imageKey=HEME%2F112300\" class=\"graphic graphic_picture graphicRef112300 \">picture 4</a>). These findings are similar to those in individuals who have undergone splenectomy and subsequently developed isolated AIHA during recovery from babesiosis. (See <a href=\"#H3\" class=\"local\">'Underlying causes'</a> above.)</p><p>It is important to recognize ES and to test for these various underlying immune disorders [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/47\" class=\"abstract_t\">47</a>], as ES is more difficult to treat and has a higher mortality than AIHA presenting alone. (See <a href=\"topic.htm?path=apoptosis-and-autoimmune-disease#H9\" class=\"medical medical_review\">&quot;Apoptosis and autoimmune disease&quot;, section on 'Autoimmune lymphoproliferative syndrome'</a> and <a href=\"topic.htm?path=warm-autoimmune-hemolytic-anemia-treatment#H19\" class=\"medical medical_review\">&quot;Warm autoimmune hemolytic anemia: Treatment&quot;, section on 'Evans syndrome'</a> and <a href=\"topic.htm?path=autoimmune-lymphoproliferative-syndrome-alps-management-and-prognosis\" class=\"medical medical_review\">&quot;Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The major differential diagnosis of warm AIHA includes hemolytic anemia due to drugs and AIHA due to the presence of cold agglutinins. Accordingly, a complete drug history is required as well as a history of the relationship, if any, between the onset of hemolysis and exposure to a drug known to be associated with warm AIHA or exposure to cold. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>AIHA due to drugs</strong> &ndash; A number of drugs can cause hemolytic anemia through an immune mechanism (<a href=\"image.htm?imageKey=HEME%2F75322\" class=\"graphic graphic_table graphicRef75322 \">table 3</a>), resulting in a positive direct antiglobulin (Coombs) test (<a href=\"image.htm?imageKey=HEME%2F69817\" class=\"graphic graphic_table graphicRef69817 \">table 2</a>). (See <a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs#H15\" class=\"medical medical_review\">&quot;Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs&quot;, section on 'Drug-related immune hemolysis'</a> and <a href=\"topic.htm?path=hemolytic-anemia-due-to-drugs-and-toxins\" class=\"medical medical_review\">&quot;Hemolytic anemia due to drugs and toxins&quot;</a>.)</p><p/><p>The immunosuppressive modalities used in warm agglutinin AIHA are generally not effective in cold agglutinin AIHA, which is generally due to the presence of IgM autoantibodies. Thus, distinction between warm and cold agglutinin AIHA is important for the selection of the proper treatment (<a href=\"image.htm?imageKey=HEME%2F69817\" class=\"graphic graphic_table graphicRef69817 \">table 2</a>). The two most common conditions causing cold agglutinin AIHA are listed below:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>AIHA due to cold agglutinins</strong> &ndash; Symptoms of acral cyanosis upon exposure to cold temperatures and a direct Coombs test that is positive for C3 but not IgG are suggestive features; the diagnosis is confirmed by documenting the presence of high titers of cold agglutinins in the serum. (See <a href=\"topic.htm?path=cold-agglutinin-disease\" class=\"medical medical_review\">&quot;Cold agglutinin disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Paroxysmal cold hemoglobinuria</strong> &ndash; Patients with paroxysmal cold hemoglobinuria (PCH) typically present with intravascular hemolysis, hemoglobinemia, and darkly colored urine (hemoglobinuria), beginning a few minutes to several hours after exposure to cold along with the presence of an IgG antibody that reacts with the red cell at reduced temperature but not at 37&deg;C and causes hemolysis on rewarming (ie, a positive Donath-Landsteiner antibody test). The direct antiglobulin (Coombs) test is positive for the presence of complement, but not IgG, during the acute hemolytic episode. (See <a href=\"topic.htm?path=paroxysmal-cold-hemoglobinuria\" class=\"medical medical_review\">&quot;Paroxysmal cold hemoglobinuria&quot;</a>.)</p><p/><p>Patients with inherited causes of anemia often have evidence for hemolysis along with the presence of spherocytes on the peripheral blood smear and may not be easily distinguished from those with warm AIHA. As an example:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hereditary</strong> <strong>spherocytosis</strong> &ndash; Patients with hereditary spherocytosis (HS) with life-long mild to moderate degrees of spherocytic hemolytic anemia may not be diagnosed until they become symptomatic following a concurrent illness or episode of transient aplasia due to parvovirus infection. A negative Coombs test and a positive personal <span class=\"nowrap\">and/or</span> family history of anemia help to distinguish HS from warm AIHA. (See <a href=\"topic.htm?path=hereditary-spherocytosis#H15480294\" class=\"medical medical_review\">&quot;Hereditary spherocytosis&quot;, section on 'Evaluation'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">DISEASE ASSOCIATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two potential disease associations with warm AIHA are the development of a lymphoproliferative disorder and venous thromboembolic disease. Rarely, a pregnant woman with warm AIHA may deliver an affected child due to placental transfer of her autoantibody.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Lymphoproliferative disorder</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The onset of idiopathic warm or cold AIHA may either precede or follow the diagnosis of a lymphoproliferative disorder (LPD) [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/50\" class=\"abstract_t\">50</a>]. A LPD is suspected when the patient with a new or prior diagnosis of warm AIHA develops systemic symptoms (eg, weight loss, night sweats, fever), lymphadenopathy, <span class=\"nowrap\">and/or</span> the presence of abnormal white blood cells on the peripheral blood smear. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma#H8\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of non-Hodgkin lymphoma&quot;, section on 'Patient history'</a>.)</p><p>In one series of 107 patients with idiopathic AIHA, 18 percent developed a malignant lymphoproliferative disorder (LPD) after a median time of approximately two years (range: 9 to 76 months) [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/51\" class=\"abstract_t\">51</a>]. The following were risk factors for development of LPD in this group of patients:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Advanced age</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Underlying autoimmune disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The presence of a monoclonal IgM gammopathy</p><p/><p>AIHA may also follow the use of purine analog therapy in patients with chronic lymphocytic leukemia or other indolent non-Hodgkin lymphoma variants. (See <a href=\"topic.htm?path=autoimmune-complications-following-purine-analog-therapy\" class=\"medical medical_review\">&quot;Autoimmune complications following purine analog therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Venous thromboembolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An increased risk for venous thromboembolism (VTE), occasionally fatal, has been described in adults with idiopathic AIHA [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/18,52-54\" class=\"abstract_t\">18,52-54</a>] as well as in those with AIHA and underlying HIV infection [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/55-57\" class=\"abstract_t\">55-57</a>]. VTE may be especially common following splenectomy for inherited and acquired hemolytic anemias, including AIHA. In one study, for example, of nine patients with warm AIHA who underwent splenectomy, four developed post-operative portal vein thrombosis and a fifth developed pulmonary embolism [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/18\" class=\"abstract_t\">18</a>]. (See <a href=\"topic.htm?path=approach-to-the-adult-with-splenomegaly-and-other-splenic-disorders#H6170429\" class=\"medical medical_review\">&quot;Approach to the adult with splenomegaly and other splenic disorders&quot;, section on 'Splenectomy'</a>.)</p><p>While the presence of antiphospholipid antibodies or a &quot;lupus anticoagulant&quot; in 19 patients with AIHA was found to be a significant risk factor for the development of VTE in one study [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/58\" class=\"abstract_t\">58</a>], this was not confirmed in a second report of 16 such patients [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/59\" class=\"abstract_t\">59</a>]. Whether patients with warm AIHA and antiphospholipid antibodies or a lupus anticoagulant should receive prophylactic anticoagulation to prevent or reduce the risk of VTE is therefore an open question. (See <a href=\"topic.htm?path=clinical-manifestations-of-antiphospholipid-syndrome#H11\" class=\"medical medical_review\">&quot;Clinical manifestations of antiphospholipid syndrome&quot;, section on 'Thrombotic events'</a>.)</p><p class=\"headingAnchor\" id=\"H13685761\"><span class=\"h2\">AIHA in the newborn</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Warm AIHA may be exacerbated during pregnancy and, in rare instances the mother&rsquo;s autoantibody may cross the placenta and affect her fetus or newborn [<a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/60-62\" class=\"abstract_t\">60-62</a>]. In some cases the newborn may only show a positive direct antiglobulin (Coombs) test, while some may develop severe anemia and require treatment (eg, phototherapy, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a>). (See <a href=\"topic.htm?path=management-of-non-rhesus-d-red-blood-cell-alloantibodies-during-pregnancy#H8\" class=\"medical medical_review\">&quot;Management of non-Rhesus (D) red blood cell alloantibodies during pregnancy&quot;, section on 'Warm autoimmune hemolytic anemia'</a>.)</p><p class=\"headingAnchor\" id=\"H288088480\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-anemia-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Anemia in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=autoimmune-hemolytic-anemia-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Autoimmune hemolytic anemia (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Etiology</strong> &ndash; The cause in most cases of warm agglutinin autoimmune hemolytic anemia (AIHA) is unknown. In a minority of cases, an associated disorder may be present. These include (see <a href=\"#H2\" class=\"local\">'Etiology'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Preceding viral infection, usually in children</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Autoimmune disorders, especially systemic lupus erythematosus</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Lymphoproliferative diseases (eg, chronic lymphocytic leukemia)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Disorders of immune <span class=\"nowrap\">deficiency/regulation</span> (eg, common variable immunodeficiency)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Drugs (eg, penicillin, <a href=\"topic.htm?path=methyldopa-drug-information\" class=\"drug drug_general\">methyldopa</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Allogeneic blood transfusion or ABO-incompatible hematopoietic cell transplantation</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Clinical manifestations</strong> &ndash; The clinical syndrome seen with AIHA of the warm-antibody type varies greatly with the amount and effectiveness of the causative antibody (see <a href=\"#H6\" class=\"local\">'Clinical manifestations'</a> above).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>When the amount is small or the antibody is inefficient at effecting hemolysis, the patient may be asymptomatic even if slightly anemic.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>More commonly, the patient may complain of shortness of breath and dyspnea on exertion. If the hemolysis is severe and of sudden onset, symptoms may be those of severe degrees of cardiac decompensation, including heart failure, arrhythmia, <span class=\"nowrap\">and/or</span> chest pain, constituting a medical emergency.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Physical examination usually reveals pallor, jaundice, and moderate splenomegaly. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Laboratory testing</strong> &ndash; Recommended laboratory tests to document the presence and extent of AIHA include the following (see <a href=\"#H8\" class=\"local\">'Laboratory findings'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Complete blood count with red blood cell indices (eg, MCV, MCH, MCHC), reticulocyte percentage, and examination of the peripheral blood smear</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Tests for hemolysis, including indirect bilirubin, lactate dehydrogenase, and haptoglobin</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Direct antiglobulin (Coombs) testing, including testing for both IgG and C3 on the red cell surface </p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Testing for specificity of the antibody for antigens identified on red blood cells</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diagnosis</strong> &ndash; Accurate diagnosis requires documentation of the following features (see <a href=\"#H8244746\" class=\"local\">'Diagnosis'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Anemia is usually present and may be severe. The mean corpuscular hemoglobin concentrations (MCHC) is increased, reflecting spherocytosis. If anemia has been present long enough, the absolute reticulocyte count and the mean corpuscular volume (MCV) will be elevated, reflecting the bone marrow's response to anemia.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Laboratory findings indicating the presence of hemolysis include elevated levels of indirect bilirubin and lactate dehydrogenase, along with reduced levels of haptoglobin. (See <a href=\"topic.htm?path=diagnosis-of-hemolytic-anemia-in-the-adult#H16\" class=\"medical medical_review\">&quot;Diagnosis of hemolytic anemia in the adult&quot;, section on 'Diagnostic approach'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The peripheral blood smear shows the presence of spherocytes, usually with an increased number of polychromatophilic red cells (reticulocytes) (<a href=\"image.htm?imageKey=HEME%2F53523\" class=\"graphic graphic_picture graphicRef53523 \">picture 2</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The diagnosis of warm agglutinin AIHA is based upon detection of antibody <span class=\"nowrap\">and/or</span> complement components on the surface of the RBC, usually by the direct antiglobulin (Coombs) test. Ninety-seven to 99 percent of patients with warm agglutinin AIHA will exhibit a positive result with anti-IgG, anti-C3, or both. (See <a href=\"#H9\" class=\"local\">'Positive antiglobulin (Coombs) test'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The differential diagnosis of warm AIHA includes AIHA due to drugs or cold agglutinins, paroxysmal cold hemoglobinuria, and hereditary spherocytosis. (See <a href=\"#H10\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Treatment</strong> &ndash; Treatment of warm agglutinin AIHA is discussed separately. (See <a href=\"topic.htm?path=warm-autoimmune-hemolytic-anemia-treatment\" class=\"medical medical_review\">&quot;Warm autoimmune hemolytic anemia: Treatment&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1560396357\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate would like to acknowledge Wendell F Rosse, MD, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/1\" class=\"nounderline abstract_t\">Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002; 69:258.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Petz LD. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 2001; 8:411.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Leaf RK, O'Brien KL, Leaf DE, Drews RE. Autoimmune hemolytic anemia in a young man with acute hepatitis E infection. Am J Hematol 2017; 92:E77.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Young PP, Uzieblo A, Trulock E, et al. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion 2004; 44:67.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Hoffman PC. Immune hemolytic anemia--selected topics. Hematology Am Soc Hematol Educ Program 2009; :80.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Ahmed I, Teruya J, Murray-Krezan C, Krance R. The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant. Pediatr Transplant 2015; 19:391.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Gonzalez H, Leblond V, Azar N, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998; 40:113.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91:341.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Byrd JC, Hertler AA, Weiss RB, et al. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 1995; 6:300.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Fleischman RA, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am J Hematol 1995; 48:293.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Tertian G, Cartron J, Bayle C, et al. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38:359.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997; 39 Suppl 1:S41.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Quinquenel A, Al Nawakil C, Baran-Marszak F, et al. Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients. Am J Hematol 2015; 90:E5.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">Woolley AE, Montgomery MW, Savage WJ, et al. Post-Babesiosis Warm Autoimmune Hemolytic Anemia. N Engl J Med 2017; 376:939.</a></li><li class=\"breakAll\">Jones J. Transfusion in oligemia. In: Blood Transfusion in Clinical Medicine, 8th ed, Mollison PL, Engelfriet CP, Contreras M (Eds), Blackwell, Oxford 1987. p.41.</li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998; 279:217.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/18\" class=\"nounderline abstract_t\">Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. Am J Hematol 2014; 89:E150.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood 1987; 69:820.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 2013; 163:393.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood 2014; 124:2930.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980; 243:1909.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Galen RS. Application of the predictive value model in the analysis of test effectiveness. Clin Lab Med 1982; 2:685.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">Mantripragada K, Quesenberry PJ. Doublet spherocytes. Blood 2014; 124:12.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">Joshi P, Aggarwal A, Jamwal M, et al. A comparative evaluation of Eosin-5'-maleimide flow cytometry reveals a high diagnostic efficacy for hereditary spherocytosis. Int J Lab Hematol 2016; 38:520.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Chaplin H Jr. Clinical usefulness of specific antiglobulin reagents in autoimmune hemolytic anemias. Prog Hematol 1973; 8:25.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Wheeler CA, Calhoun L, Blackall DP. Warm reactive autoantibodies: clinical and serologic correlations. Am J Clin Pathol 2004; 122:680.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Sachs UJ, R&ouml;der L, Santoso S, Bein G. Does a negative direct antiglobulin test exclude warm autoimmune haemolytic anaemia? A prospective study of 504 cases. Br J Haematol 2006; 132:655.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Meulenbroek EM, Wouters D, Zeerleder SS. Lyse or not to lyse: Clinical significance of red blood cell autoantibodies. Blood Rev 2015; 29:369.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Podberezin M, Levina A, Romanova L, et al. Quantitation of red cell-bound immunoglobulins and complement in lymphoma patients. Immunohematology 2000; 16:147.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">Bencomo AA, Diaz M, Alfonso Y, et al. Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay. Immunohematology 2003; 19:47.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Nathalang O, Chuansumrit A, Prayoonwiwat W, et al. Comparison between the conventional tube technique and the gel technique in direct antiglobulin tests. Vox Sang 1997; 72:169.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Lin JS, Hao TC, Lyou JY, et al. Clinical application of a flow cytometric direct antiglobulin test. Transfusion 2009; 49:1335.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">Garratty G, Arndt P, Domen R, et al. Severe autoimmune hemolytic anemia associated with IgM warm autoantibodies directed against determinants on or associated with glycophorin A. Vox Sang 1997; 72:124.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/35\" class=\"nounderline abstract_t\">Reusser P, Osterwalder B, Burri H, Speck B. Autoimmune hemolytic anemia associated with IgA--diagnostic and therapeutic aspects in a case with long-term follow-up. Acta Haematol 1987; 77:53.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">Janvier D, Sellami F, Missud F, et al. Severe autoimmune hemolytic anemia caused by a warm IgA autoantibody directed against the third loop of band 3 (RBC anion-exchange protein 1). Transfusion 2002; 42:1547.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Bardill B, Mengis C, Tschopp M, Wuillemin WA. Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old woman. Eur J Haematol 2003; 70:60.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Arndt PA, Leger RM, Garratty G. Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. Transfusion 2009; 49:235.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Bartolm&auml;s T, Salama A. A dual antiglobulin test for the detection of weak or nonagglutinating immunoglobulin M warm autoantibodies. Transfusion 2010; 50:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Thedsawad A, Taka O, Wanachiwanawin W. Significances of red cell bound immunoglobulin G as detected by flow cytometry in patients with Coombs-negative immune hemolysis. Transfus Med 2016; 26:130.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">Kamesaki T, Oyamada T, Omine M, et al. Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol 2009; 84:98.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/42\" class=\"nounderline abstract_t\">Kamesaki T, Toyotsuji T, Kajii E. Characterization of direct antiglobulin test-negative autoimmune hemolytic anemia: a study of 154 cases. Am J Hematol 2013; 88:93.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/43\" class=\"nounderline abstract_t\">Conley CL, Lippman SM, Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA 1980; 244:1688.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/44\" class=\"nounderline abstract_t\">Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009; 114:3167.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/45\" class=\"nounderline abstract_t\">Sava&#351;an S, Warrier I, Buck S, et al. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans' syndrome. Clin Immunol 2007; 125:224.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/46\" class=\"nounderline abstract_t\">Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 2005; 105:2443.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/47\" class=\"nounderline abstract_t\">Seif AE, Manno CS, Sheen C, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood 2010; 115:2142.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/48\" class=\"nounderline abstract_t\">Stepensky P, Rensing-Ehl A, Gather R, et al. Early-onset Evans syndrome, immunodeficiency, and premature immunosenescence associated with tripeptidyl-peptidase II deficiency. Blood 2015; 125:753.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/49\" class=\"nounderline abstract_t\">Shatzel JJ, Donohoe K, Chu NQ, et al. Profound autoimmune hemolysis and Evans syndrome in two asplenic patients with babesiosis. Transfusion 2015; 55:661.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/50\" class=\"nounderline abstract_t\">Genty I, Michel M, Hermine O, et al. [Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases]. Rev Med Interne 2002; 23:901.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/51\" class=\"nounderline abstract_t\">Sallah S, Wan JY, Hanrahan LR. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. Clin Cancer Res 2001; 7:791.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/52\" class=\"nounderline abstract_t\">Allgood JW, Chaplin H Jr. Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. Am J Med 1967; 43:254.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/53\" class=\"nounderline abstract_t\">Hendrick AM. Auto-immune haemolytic anaemia--a high-risk disorder for thromboembolism? Hematology 2003; 8:53.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/54\" class=\"nounderline abstract_t\">Yusuf HR, Hooper WC, Beckman MG, et al. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis 2014; 38:306.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/55\" class=\"nounderline abstract_t\">Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15:311.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/56\" class=\"nounderline abstract_t\">Yusuf HR, Hooper WC, Grosse SD, et al. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res 2015; 135:50.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/57\" class=\"nounderline abstract_t\">Ungprasert P, Tanratana P, Srivali N. Autoimmune hemolytic anemia and venous thromboembolism: A systematic review and meta-analysis. Thromb Res 2015; 136:1013.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/58\" class=\"nounderline abstract_t\">Pullarkat V, Ngo M, Iqbal S, et al. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol 2002; 118:1166.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/59\" class=\"nounderline abstract_t\">Comellas-Kirkerup L, Hern&aacute;ndez-Molina G, Cabral AR. Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study. Blood 2010; 116:3058.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/60\" class=\"nounderline abstract_t\">Sokol RJ, Hewitt S, Stamps BK. Erythrocyte autoantibodies, autoimmune haemolysis and pregnancy. Vox Sang 1982; 43:169.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/61\" class=\"nounderline abstract_t\">Lawe JE. Successful exchange transfusion of an infant for AIHA developing late in mother's pregnancy. Transfusion 1982; 22:66.</a></li><li><a href=\"https://www.uptodate.com/contents/warm-autoimmune-hemolytic-anemia-clinical-features-and-diagnosis/abstract/62\" class=\"nounderline abstract_t\">Williamson TD, Liles LH, Blackall DP. A maternal warm-reactive autoantibody presenting as a positive direct antiglobulin test in a neonate. Immunohematology 1997; 13:6.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7078 Version 31.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">ETIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Underlying causes</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Drugs</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">LABORATORY FINDINGS</a><ul><li><a href=\"#H8244760\" id=\"outline-link-H8244760\">Hemolytic anemia</a></li><li><a href=\"#H8244772\" id=\"outline-link-H8244772\">Spherocytosis</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Positive antiglobulin (Coombs) test</a><ul><li><a href=\"#H10336022\" id=\"outline-link-H10336022\">- Direct Coombs test</a></li><li><a href=\"#H10336035\" id=\"outline-link-H10336035\">- Indirect Coombs test</a></li><li><a href=\"#H10556119\" id=\"outline-link-H10556119\">- Coombs-negative AIHA</a></li></ul></li><li><a href=\"#H2760904\" id=\"outline-link-H2760904\">Reticulocyte response</a></li><li><a href=\"#H8244802\" id=\"outline-link-H8244802\">Other findings</a></li></ul></li><li><a href=\"#H8244746\" id=\"outline-link-H8244746\">DIAGNOSIS</a></li><li><a href=\"#H7149664\" id=\"outline-link-H7149664\">EVANS SYNDROME</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">DISEASE ASSOCIATIONS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Lymphoproliferative disorder</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Venous thromboembolism</a></li><li><a href=\"#H13685761\" id=\"outline-link-H13685761\">AIHA in the newborn</a></li></ul></li><li><a href=\"#H288088480\" id=\"outline-link-H288088480\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H109734965\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1560396357\" id=\"outline-link-H1560396357\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/7078|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/100639\" class=\"graphic graphic_figure\">- Direct and indirect antiglobulin (Coombs) testing</a></li></ul></li><li><div id=\"HEME/7078|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/110026\" class=\"graphic graphic_picture\">- Blood smear - Babesia</a></li><li><a href=\"image.htm?imageKey=HEME/53523\" class=\"graphic graphic_picture\">- Warm reactive AIHA</a></li><li><a href=\"image.htm?imageKey=HEME/50601\" class=\"graphic graphic_picture\">- Nucleated RBC in AIHA</a></li><li><a href=\"image.htm?imageKey=HEME/112300\" class=\"graphic graphic_picture\">- Blood smear ES, splenectomized recovering from babesiosis</a></li></ul></li><li><div id=\"HEME/7078|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/97136\" class=\"graphic graphic_table\">- Warm AIHA characteristics</a></li><li><a href=\"image.htm?imageKey=HEME/69817\" class=\"graphic graphic_table\">- Coombs test in AIHA</a></li><li><a href=\"image.htm?imageKey=HEME/75322\" class=\"graphic graphic_table\">- Drugs immune hemolytic anemia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=apoptosis-and-autoimmune-disease\" class=\"medical medical_review\">Apoptosis and autoimmune disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-anemia\" class=\"medical medical_review\">Approach to the adult with anemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-splenomegaly-and-other-splenic-disorders\" class=\"medical medical_review\">Approach to the adult with splenomegaly and other splenic disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-complications-following-purine-analog-therapy\" class=\"medical medical_review\">Autoimmune complications following purine analog therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-lymphoproliferative-syndrome-alps-clinical-features-and-diagnosis\" class=\"medical medical_review\">Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-lymphoproliferative-syndrome-alps-management-and-prognosis\" class=\"medical medical_review\">Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-antiphospholipid-syndrome\" class=\"medical medical_review\">Clinical manifestations of antiphospholipid syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-epidemiology-and-diagnosis-of-common-variable-immunodeficiency-in-adults\" class=\"medical medical_review\">Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma\" class=\"medical medical_review\">Clinical presentation and diagnosis of non-Hodgkin lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cold-agglutinin-disease\" class=\"medical medical_review\">Cold agglutinin disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-hemolytic-anemia-in-the-adult\" class=\"medical medical_review\">Diagnosis of hemolytic anemia in the adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=donor-selection-for-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Donor selection for hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-the-patient-with-suspected-heart-failure\" class=\"medical medical_review\">Evaluation of the patient with suspected heart failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematologic-manifestations-of-hiv-infection-anemia\" class=\"medical medical_review\">Hematologic manifestations of HIV infection: Anemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematologic-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">Hematologic manifestations of systemic lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemolytic-anemia-due-to-drugs-and-toxins\" class=\"medical medical_review\">Hemolytic anemia due to drugs and toxins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatitis-e-virus-infection\" class=\"medical medical_review\">Hepatitis E virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hereditary-spherocytosis\" class=\"medical medical_review\">Hereditary spherocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult\" class=\"medical medical_review\">Indications and hemoglobin thresholds for red blood cell transfusion in the adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=macrocytosis-macrocytic-anemia\" class=\"medical medical_review\">Macrocytosis/Macrocytic anemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-non-rhesus-d-red-blood-cell-alloantibodies-during-pregnancy\" class=\"medical medical_review\">Management of non-Rhesus (D) red blood cell alloantibodies during pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-complications-of-chronic-lymphocytic-leukemia\" class=\"medical medical_review\">Overview of the complications of chronic lymphocytic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paroxysmal-cold-hemoglobinuria\" class=\"medical medical_review\">Paroxysmal cold hemoglobinuria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-cold-agglutinin-disease\" class=\"medical medical_review\">Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs\" class=\"medical medical_review\">Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-hemolytic-anemia-the-basics\" class=\"medical medical_basics\">Patient education: Autoimmune hemolytic anemia (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-anemia-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Anemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-incompatible-crossmatch\" class=\"medical medical_review\">The incompatible crossmatch</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=warm-autoimmune-hemolytic-anemia-treatment\" class=\"medical medical_review\">Warm autoimmune hemolytic anemia: Treatment</a></li></ul></div></div>","javascript":null}